Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy

Journal of Cellular Biochemistry

Volumn 104, Issue 6, 2008, Pages 2059-2070

  Lübbert, Michael ^a   Müller Tidow, Carsten ^b   Hofmann, Wolf Karsten ^c   Koeffler, H Phillip ^d,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Myelodysplasia; Translocations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; CYTARABINE; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LENALIDOMIDE; NUCLEOSIDE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; THALIDOMIDE DERIVATIVE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOGENETICS; DEMETHYLATION; DISEASE MODEL; DNA METHYLATION; DRUG MEGADOSE; GENOMICS; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SKIN TOXICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

CHROMOSOME ABERRATIONS; CYTOGENETICS; EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 49049100885     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21770     Document Type: Conference Paper

References (72)

1. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Sciurpi MT, Mariano AR, Minardi SP, Luzi L, Müller H, Di Fiore PP, Frosina G, Pelicci PG. 2003. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112:1751-1761.
2. Araki H, Mahmud N, Milhem M, Nunez R, Xu M, Beam CA, Hoffman R. 2006. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol 34:140-149.
3. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lübbert M. 2007. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 31:497-506.
4. Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T, Boehrer S, Hoelzer D, Ottmann OG, Ruthardt M. 2005a. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 65:2537-2541.
5. Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG. 2005b. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104:2717-2725.
6. Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley KA. 2007. Comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109(6):1114-1124.
7. Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG, Minucci S. 2006. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26:1288-1296.
8. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C. 2006. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 66:8903-8911.
9. Claus R, Fliegauf M, Stock M, Duque JA, Kolanczyk M, Lübbert M. 2006. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression. J Leukoc Biol 80:1462-1472.
10. Deschler B, Lübbert M. 2006. Acute myeloid leukemia: Epidemiology and etiology. Cancer 107:2099-2107.
11. Deschler B, de Witte T, Mertelsmann R, Lübbert M. 2006. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: Problems and approaches. Haematologica 91:1513-1522.
12. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. 2007. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 21:1026-1034.
13. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Lo Coco F, Kouzarides T, Nervi C, Minucci S, Pelicci PG. 2002. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082.
14. Downing JR. 1999. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: Biology and clinical significance. Br J Haematol 106:296-308.
15. Dunne J, Cullmann C, Ritter M, Soria NM, Drescher B, Debernardi S, Skoulakis S, Hartmann O, Krause M, Krauter J, Neubauer A, Young BD, Heidenreich O. 2006. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene 25:6067-6078.
16. Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. 1992. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80:1825-1831.
17. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. 1999. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93(8):2478-2484.
18. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, List AF, Gore SD, Seymour JF, Hellström-Lindberg E, Bennett JM, Byrd JC, Backstrom JT, Zimmerman LS, McKenzie DR, Beach CL, Silverman LR. 2007. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): Results of the AZA-001 phase III study. Blood 110(suppl.):abs. 817.
19. Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. 2005. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol 23:1921-1926.
20. Fliegauf M, Stock M, Berg T, Lübbert M. 2004. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: A novel target gene of AML1/ETO. Oncogene 23:9070-9081.
21. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. 2006. Phase 1/2 study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279.
22. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I., et al. 1993. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423-431.
23. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818.
24. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP, Nordheim A. 2003. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101:3157-3163.
25. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572.
26. Joslin JM, Fernald AA, Tennant TR, Davis EM, Kogan SC, Anastasi J, Crispino JD, Le Beau MM. 2007. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110:719-726.
27. Kamashev D, Vitoux D, de The H. 2004. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199:1163-1174.
28. Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, Ichikawa-Iwata E, Zhong S, Pandolfi PP, Ishii S. 2001. Role of PML and PML-RARalpha in Madmediated transcriptional repression. Mol Cell 7:1233-1243.
29. Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. 2003. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17:350-358.
30. Koeffler HP. 1983. Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 62:709-721.
31. Krones-Herzig A, Mittal S, Yule K, Liang H, English C, Urcis R, Soni T, Adamson ED, Mercola D. 2005. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53. Cancer Res 65:5133-5143.
32. Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N. 2004. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266-1269.
33. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N. 2005. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 84 (Suppl 1):61-66.
34. Lausen J, Liu S, Fliegauf M, Lübbert M, Werner MH. 2006. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO. Oncogene 25:1349-1357.
35. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. 2007. Common deleted genes in the 5q-syndrome: Thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia 21:1931-1936.
36. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465.
37. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT. 2007. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13:78-83.
38. Lübbert M. 2005. Combined targeting of the epigenetic silence in leukemia: Cooperating activities of DNA methylation and histone deacetylation inhibitors. Leuk Res 29:727-728.
39. Lübbert M, Herrmann F, Koeffler HP. 1991. Expression and regulation of myeloid-specific genes in normal and leukemic myeloid cells. Blood 77:909-924.
40. Lübbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly S, Ravoet C, Andre M, Ferrant A. 2001. Cytogenetic normalization in high-risk myelodysplastic syndrome following continued low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine (decitabine). Br J Haemat 114:349-357.
41. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176-7184.
42. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. 2000. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST I571:diverse mechanisms of resistance. Blood 96:1070-1079.
43. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C, Pelicci PG, Müller H, Alcalay M. 2005. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia. Oncogene 24:3358-3368.
44. Meyers S, Downing JR, Hiebert SW. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: The runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13:6336-6345.
45. Milhem M, Mahmud N, Lavelle D, Araki H, DeSimone J, Saunthararajah Y, Hoffman R. 2004. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103:4102-4110.
46. Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A, Diverio D, Gasparini P, Capillo M, Colombo E, Matteucci C, Contegno F, Lo-Coco F, Scanziani E, Gobbi A, Pelicci PG. 2002. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100:2989-2995.
47. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. 1991. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, A ML1. Proc Natl Acad Sci USA 88:10431-10434.
48. Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H. 2004. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 24:2890-2904.
49. Park DJ, Vuong PT, de Vos S, Douer D, Koeffler HP. 2003. Comparative analysis of genes regulated by PML/RAR alpha and PLZF/RAR alpha in response to retinoic acid using oligonucleotide arrays. Blood 102:3727-3736.
50. Pellagatti A, Jadersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK, Merup M, Nilsson L, Samuelsson J, Sander B, Wainscoat JS, Boultwood J, Hellstrom-Lindberg E. 2007. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 104:11406-11411.
51. Peterson LF, Zhang DE. 2004. The 8;21 translocation in leukemogenesis. Oncogene 23:4255-4262.
52. Pinto A, Zagonel V, Attacha V, Bullian PL, Gattei V, Carbone A, Monfardini S, Colombatti A. 1989. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marrow Transplant 4 (Suppl 3):28-32.
53. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti GJ. 2007. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21:1937-1944.
54. Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fang M. 2005. Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma. Cancer 104:925-930.
55. Schlenk RF, Fröhling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W, Gotze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B, Döhner K, Haas R, Döhner H. 2004. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18:1798-1803.
56. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360.
57. Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, Kitabayashi I, Ohki M. 2000. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MT G8:overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 96:655-663.
58. Silverman LR, Holland JF, Weinberg RS, et al. 1993. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:S21-S29.
59. Silverman LR, Holland JF, Demakos EP. 1994. Azacitidine (AzaC) in myelodysplastic syndromes (MDS), CALGB Studies 8421 and 8921. Ann Hemat 68:S21a.
60. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. 2002. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440.
61. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. 2007. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110:2302-2308.
62. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. 2004. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet 36:257-263.
63. Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD. 2005. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 19:1161-1168.
64. Tussie-Luna MI, Rozo L, Roy AL. 2006. Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia. Oncogene 25:3375-3386.
65. Villa R, Morey L, Raker VA, Buschbeck M, Gutierrez A, De Santis F, Corsaro M, Varas F, Bossi D, Minucci S, Pelicci PG, Di Croce L. 2006. The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc Natl Acad Sci USA 103:1400-1405.
66. Walter MJ, Park JS, Lau SK, Li X, Lane AA, Nagarajan R, Shannon WD, Ley TJ. 2004. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures. Mol Cell Biol 24:10882-10893.
67. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. 1998. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860-10865.
68. Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB, Popescu NC, DiPersio JF, Ley TJ. 2003. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102:1857-1865.
69. Wijermans PW, Lübbert M, Verhoef G, Klimek V, Bosly A. 2005. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84 (Suppl 1):9-17.
70. Yang AS, Doshi KD, Choi SW, Mason JB, Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, Kantarjian HM, Garcia-Manero G, Issa JP. 2006. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495-5503.
71. Zhou J, Peres L, Honore N, Nasr R, Zhu J, de The H. 2006. Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA 103:9238-9243.
72. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, de The H. 2005. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell 7: 143-153.